Synergistic Effects of Family History of Hepatocellular Carcinoma and Hepatitis B Virus Infection on Risk for Incident Hepatocellular Carcinoma

• Published in: Clinical gastroenterology and hepatology Vol. 11; no. 12; pp. 1636 - 1645.e3
• Main Authors: Loomba, Rohit, Liu, Jessica, Yang, Hwai–I., Lee, Mei–Hsuan, Lu, Sheng–Nan, Wang, Li–Yu, Iloeje, Uchenna H., You, San–Lin, Brenner, David, Chen, Chien–Jen
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2013
• Subjects: Adult; Aged; Cancer Risk Factor; Carcinoma, Hepatocellular - epidemiology; Cirrhosis; Cohort Studies; Epidemiology; Family Health; Female; Gastroenterology and Hepatology; Hepatitis B, Chronic - complications; Humans; Liver Disease; Liver Neoplasms - epidemiology; Male; Middle Aged; Risk Assessment; Taiwan - epidemiology; Taiwan; CI; HBeAg; HBsAg; HCC; HR; RERI; REVEAL; Epidemiology; AP; Cirrhosis; SI; Liver Disease; Cancer Risk Factor; HBV; attributable proportion; relative excess risk caused by interaction; hepatitis B surface antigen; hepatitis B virus; hepatitis B e antigen; synergy index; hazard ratio; confidence interval; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus; hepatocellular carcinoma
• ISSN: 1542-3565; 1542-7714; 1542-7714
• DOI: 10.1016/j.cgh.2013.04.043

Little is known about the effects of family history of hepatocellular carcinoma (HCC) on hepatitis B progression or risk of HCC. We examined how family HCC history and presence or stage of hepatitis B virus (HBV) infection affect risk for HCC. We performed a population-based cohort study of 22,472 participants from 7 townships in Taiwan who underwent evaluation for liver disease from 1991 through 1992. Those who received a first diagnosis of HCC from January 1, 1991, to December 31, 2008, were identified from the Taiwanese cancer registry. There were 374 cases of incident HCC over 362,268 person-years of follow-up evaluation. The cumulative risk of HCC in hepatitis B surface antigen (HBsAg)-seronegative patients without a family history of HCC was 0.62%, in those with a family history of HCC the cumulative risk was 0.65%, in HBsAg-seropositive patients without a family history of HCC the cumulative risk was 7.5%, and in HBsAg-seropositive patients with a family history of HCC the cumulative risk was 15.8% (P < .001). The multivariate-adjusted hazard ratio for HBsAg-seropositive individuals with family history, compared with HBsAg-seronegative individuals without a family history of HCC, was 32.33 (95% confidence interval, 20.8–50.3; P < .001). The relative excess risk owing to interaction was 19, the attributable proportion was 0.59, and the synergy index value was 2.54. These findings indicate synergy between family HCC history and HBsAg serostatus. The synergy between these factors remained significant in stratification analyses by HBeAg serostatus and serum level of HBV DNA. Family history of HCC multiplies the risk of HCC at each stage of HBV infection. Patients with a family history of HCC require more intensive management of HBV infection and surveillance for liver cancer.